Non-a, Non-b Hepatitis Virus Or Hepatitis C Virus Patents (Class 424/228.1)
-
Patent number: 11620814Abstract: Aspects of the present disclosure describe systems, methods and structures providing contextual grounding—a higher-order interaction technique to capture corresponding context between text entities and visual objects.Type: GrantFiled: September 8, 2020Date of Patent: April 4, 2023Inventors: Farley Lai, Asim Kadav, Ning Xie
-
Patent number: 11214804Abstract: The present invention provides polynucleotide aptamers that selectively bind to and inhibit polymerization of sickle hemoglobin (HbS), pharmaceutical compositions comprising the same, methods of use for diagnostics and treatment of sickle cell disease, methods of use as capture reagents, and methods of rational drug design.Type: GrantFiled: December 17, 2019Date of Patent: January 4, 2022Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: James F. Casella, Emily Barron-Casella, Jeffrey R. Keefer, Yolanda Fortenberry, Shirley H. Purvis
-
Patent number: 10550148Abstract: In various embodiments, the present invention provides a process for separating target proteins from non-target proteins in a sample comprising increasing the concentration of the target proteins and non-target proteins in the sample and subsequently delivering the concentrated sample to a chromatography device. In other embodiments, the invention relates to a process for increasing the capacity of a chromatography device for a target protein by delivering a concentrated sample comprising the target protein to a chromatography device.Type: GrantFiled: June 11, 2015Date of Patent: February 4, 2020Assignee: EMD Millipore CorporationInventors: Venkatesh Natarajan, Herbert Lutz, Bala Raghunath
-
Patent number: 10444242Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.Type: GrantFiled: June 22, 2016Date of Patent: October 15, 2019Assignees: ABBOTT LABORATORIES, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAIInventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis, Andrea Branch, Francis Eng
-
Patent number: 10345311Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.Type: GrantFiled: June 22, 2016Date of Patent: July 9, 2019Assignee: Abbott LaboratoriesInventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
-
Patent number: 9598467Abstract: The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof.Type: GrantFiled: August 14, 2013Date of Patent: March 21, 2017Assignee: THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITEDInventors: Kathleen McCaffrey, Heidi Drummer, Pantelis Poumbourios
-
Patent number: 9175300Abstract: The present invention relates to a method of expressing a foreign protein in the plastid of a host cell and secreting said protein into the cytoplasm of the host cell comprising the steps of making a construct of vector linked to a coding sequence of the fusion protein comprising of signal peptide sequence followed by in-frame fusion to a foreign gene; and stably integrating said construct into the plastid genome. The present invention also relates to a method of targeting the expressed and secreted proteins from the plastids to the nucleus of the host cell. The present invention further relates to the method where the host cell is of any higher plant or any organism including single cell algae.Type: GrantFiled: November 27, 2009Date of Patent: November 3, 2015Inventors: Vanga Siva Reddy, Sadhu Leelavathi, Amit Bhardwaj
-
Patent number: 9000136Abstract: Provided is a recombinant virus which is efficacious in preventing the onset of hepatitis C infection and has a high safety. Also provided is a vaccine for hepatitis C virus which contains the recombinant virus. A recombinant vaccinia virus which can express hepatitis C virus gene. The hepatitis C virus vaccine as described above contains the recombinant virus as described above.Type: GrantFiled: March 6, 2009Date of Patent: April 7, 2015Assignees: Tokyo Metropolitan Institute of Medical Science, The Chemo-Sero-Therapeutic Research InstituteInventors: Michinori Kohara, Fukashi Murai
-
Patent number: 8945584Abstract: A robust and genetically stable cell culture system for Hepatitis C Virus (HCV) genotype 3a is provided. A genotype 3a/2a (S52/JFH1) recombinant containing the structural genes (Core, E1, E2), p7 and NS2 of strain S52 was constructed and characterized in Huh7.5 cells. S52/JFH1 and J6/JFH viruses passaged in cell culture had comparable growth kinetics and yielded similar peak HCV RNA titers and infectivity titers. Direct genome sequencing of cell culture derived S52/JFH1 viruses identified putative adaptive mutations in Core, E2, p7, NS3, and NS5A; clonal analysis revealed that all genomes analyzed exhibited different combinations of these mutations. Finally, viruses resulting from transfection with RNA transcripts of five S52/JFH1 recombinants containing these combinations of putative adaptive mutations performed as efficiently as J6/JFH viruses in Huh7.5 cells and were all genetically stable after viral passage.Type: GrantFiled: April 11, 2008Date of Patent: February 3, 2015Assignee: Hvidovre HospitalInventors: Judith M. Gottwein, Troels Kasper Høyer Scheel, Jesper Eugen-Olsen, Jens Bukh
-
Publication number: 20150017207Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.Type: ApplicationFiled: July 9, 2014Publication date: January 15, 2015Applicant: University of Washington through its Center for CommercializationInventors: Michael J. Gale, JR., Gretja Schnell, Yueh-Ming Loo
-
Patent number: 8932606Abstract: The construction of a chimeric Pestivirus by the identification of selected regions in the 3?NTR of the viral RNA genome is described where additional RNA sequences can be stably inserted. These sequence insertions in the viral RNA genome were stable in replication and capable of forming infectious, RNase resistant virus particles. This chimeric Pestivirus with a 3?NTR insertion can be utilized as a quality control material in analytical assays for RNA targets, including external, internal controls, quantitative standards in PCR and NAT nucleic acid assays.Type: GrantFiled: November 24, 2009Date of Patent: January 13, 2015Assignee: Life Technologies CorporationInventors: Erhard Schoenbrunner, Sven-Erik Behrens
-
Publication number: 20150010504Abstract: Disclosed are compounds of formula (I) for use as antiviral agents, particularly as anti-hepatitis virus C agents, wherein A, B, U, R1-R7, m, n, and q are as described herein. Also disclosed are pharmaceutical compositions and methods of treating or preventing viral infection in a host by the use of these compounds, either alone or in combination with other pharmaceutically active agents. Further disclosed are methods of preparing such compounds.Type: ApplicationFiled: February 9, 2013Publication date: January 8, 2015Applicant: Lupin LimitedInventors: Vidya Ramdas, Advait Arun Joshi, Moloy Manoj Banerjee, Amit Kumar Das, Deepak Sahebrao Walke, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20150010595Abstract: The invention refers to an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZSZN—XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.Type: ApplicationFiled: June 11, 2014Publication date: January 8, 2015Applicant: Valneva Austria GmbHInventors: Michael Buschle, André Habel, Jörg Fritz, Karin Prinz, Karen Lingnau
-
Patent number: 8883169Abstract: Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines.Type: GrantFiled: July 7, 2011Date of Patent: November 11, 2014Assignee: Chrontech Pharma ABInventors: Matti Sällberg, Jonas Soderholm, Lars Frelin
-
Publication number: 20140328876Abstract: In one aspect, the present disclosure provides compounds of formulae (I) and (II). In another aspect, a compound of formula (I) or (II) is formulated into compositions with an antigen, optionally with a vesicle. In some embodiments, compositions are administered intramuscularly.Type: ApplicationFiled: November 16, 2012Publication date: November 6, 2014Inventor: Maura Ellen Campbell
-
Publication number: 20140302092Abstract: A nucleic acid includes the 5? untranslated region, a virus protein-coding region including the NS3 protein coding sequence, the NS4A protein coding sequence, the NS4B protein coding sequence, the NS5A protein coding sequence, and the NS5B protein coding sequence, and the 3? untranslated region of the HCV J6CF genome in that order from the 5? to 3? direction. The NS4A protein coding sequence has a mutation for substituting alanine at position 1680 with glutamic acid, as determined on the basis of the amino acid sequence of the precursor protein of the J6CF strain.Type: ApplicationFiled: May 31, 2012Publication date: October 9, 2014Applicants: Toray Industries, Inc., Japan as Represented by Director-General of National Institute of Infectious DiseasesInventors: Takaji Wakita, Asako Murayama, Takanobu Kato
-
Publication number: 20140286995Abstract: A nucleic acid includes, in the following order, a 5? untranslated region comprising a particular nucleotide sequence of the genome of hepatitis C virus genotype 3a; a nucleotide sequence encoding a particular amino acid sequence of an NS3 protein, a nucleotide sequence encoding a particular amino acid sequence of an NS4A protein, a nucleotide sequence encoding a particular amino acid sequence of an NS4B protein, a nucleotide sequence encoding a particular amino acid sequence of an NS5A protein, a nucleotide sequence encoding a particular amino acid sequence of an NS5B protein of the hepatitis C virus genotype 3a; and a 3? untranslated region comprising a particular nucleotide sequence of a genome of hepatitis C virus genotype 3a.Type: ApplicationFiled: August 31, 2012Publication date: September 25, 2014Applicants: Japan as Represented by Director-General of National Institute of Infectious Diseases, Toray Industries, Inc., INSERM Institutut National de la Sante et de la Recherche MedicaleInventors: Takaji Wakita, Mohsan Saeed, Patrick Maurel, Claire Gondeau, Hiroshi Yokokawa
-
Patent number: 8834893Abstract: The present invention provides a nucleic acid comprises a 5? untranslated region, an NS3 protein coding region, an NS4A protein coding region, an NS4B protein coding region, an NS5A protein coding region, an NS5B protein coding region, and a 3? untranslated region of a hepatitis C virus genome, wherein the nucleic acid has nucleotide substitutions causing one or more amino acid substitutions selected from the group consisting of M(1205)K, F(1548)L, C(1615)W, T(1652)N, A(2196)T, A(2218)S, H(2223)Q, Q(2281)R, K(2520)N, and G(2374)S, as defined using the amino acid sequence shown in SEQ ID NO: 6 in the Sequence Listing as a reference sequence, in the NS3 protein coding region, the NS5A protein coding region, or the NS5B protein coding region.Type: GrantFiled: December 25, 2009Date of Patent: September 16, 2014Assignees: Toray Industries, Inc., Japan as Represented by Director-General of National Institute of Infectious Diseases, Tokyo Metropolitan Institute of Medical ScienceInventors: Takaji Wakita, Tomoko Date, Hitoshi Takahashi
-
Patent number: 8821892Abstract: Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection.Type: GrantFiled: January 8, 2013Date of Patent: September 2, 2014Assignee: GlobeImmune, Inc.Inventors: Richard C. Duke, Alex Franzusoff, Aurelia Haller, Thomas H. King
-
Publication number: 20140227320Abstract: Disclosed herein are compounds and related compositions for the treatment of viral infection, including RNA viral infection, and compounds that can modulate the RIG-I pathway in vertebrate cells, including compounds that can activate the RIG-I pathway.Type: ApplicationFiled: September 27, 2012Publication date: August 14, 2014Inventors: Shawn P. Iadonato, Kristin Bedard, Myra Wang Imanaka, Kerry W. Fowler
-
Patent number: 8784837Abstract: The invention refers an improved vaccine against infections with pathogens, especially viral pathogens, comprising an antigen, a peptide of the formula R1—XZSZN—XZX—R2 and an immunostimulatory deoxynucleic acid containing deoxyinosine and/or deoxyuridine residues.Type: GrantFiled: April 13, 2010Date of Patent: July 22, 2014Assignee: Valneva Austria GmbHInventors: Michael Buschle, André Habel, Jörg Fritz, Karin Prinz, Karen Lingnau
-
Publication number: 20140193459Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.Type: ApplicationFiled: May 3, 2013Publication date: July 10, 2014Applicant: Infectious Disease Research InstituteInventors: Steven G. Reed, Darrick Carter
-
Publication number: 20140193458Abstract: A vaccination method is provided. The method comprises administering to a mammal a histone deacytelase inhibitor in conjunction with a vaccine that expresses an antigen to which the mammal has a pre-existing immunity.Type: ApplicationFiled: March 9, 2012Publication date: July 10, 2014Inventors: Byram Bridle, Brian Lichty, Yonghong Wan, Jean-Simon Diallo, Chantal Lemay, John Bell
-
Patent number: 8772022Abstract: Hepatitis C reporter viruses containing Core through NS2 of prototype isolates of all major HCV genotypes and the remaining genes of isolate JFH1, by insertion of reporter genes in domain III of HCV NS5A were developed. A deletion upstream of the inserted reporter gene sequence conferred favorable growth kinetics in Huh7.5 cells to these viruses. These reporter viruses can be used for high throughput analysis of drug and vaccine candidates as well as patient samples. JFH1-based intergenotypic recombinants with genotype specific homotypic 5?UTR, or heterotypic 5?UTR (either of genotype 1a (strain H77) or of genotype 3a (strain S52)) were also developed. The present inventors additionally developed J6/JFH1 recombinants with the 5?UTR of genotypes 1-6. These recombinants with different 5?UTRs are a useful to study the function of the 5?UTR in a genotype specific manner.Type: GrantFiled: October 5, 2009Date of Patent: July 8, 2014Assignees: Hvidovre Hospital, Kobenhavns UniversitetInventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Jens Bukh, Jannick Prento, Tanja Bertelsen Jensen, Jacob Bo Lademann, Yiping Li
-
Publication number: 20140186292Abstract: Methods are disclosed for producing defective ribosomal products (DRiPs) in blebs (DRibbles) by contacting cells with a proteasome inhibitor, and in some examples also an autophagy inducer, thereby producing treated cells. DRibbles can be used to load antigen presenting cells (APCs), thereby allowing the APCs to present the DRiPs and antigenic fragments thereof. Immunogenic compositions that include treated cells, isolated DRibbles, or DRibble-loaded APCs are also disclosed. Methods are also provided for using treated cells, isolated DRibbles, or DRibble-loaded APCs to stimulate an immune response, for example in a subject. For example, DRibbles obtained from a tumor cell can be used to stimulate an immune response against the same type of tumor cells in the subject. In another example, DRibbles obtained from a pathogen-infected cell or cell engineered to express one or more antigens of a pathogen can be used to stimulate an immune response against the pathogen in the subject.Type: ApplicationFiled: February 10, 2014Publication date: July 3, 2014Applicant: Providence Health & Services - OregonInventor: Hong-Ming Hu
-
Patent number: 8765386Abstract: A method and device to detect Hepatitis C (HCV) antibodies in oral fluid is provided. This method introduces a non-antibody detection molecule that labels all classes of patient antibodies in oral fluid, followed by the specific concentration of labeled anti-HCV antibodies by selective capture in a trapping zone consisting of peptide antigens derived from the HCV genome. Signal generated by the labeled antibodies present in the trapping zone is proportional to the number of anti-HCV antibodies bound to the antigens present in the trapping zone. Presence of signal derived from the capture of antibody/detection molecule complexes in the trapping zone is indicative of past exposure to HCV.Type: GrantFiled: February 14, 2012Date of Patent: July 1, 2014Assignee: Instant Medical Diagnostics, LLCInventors: Jonathan Zmuda, Lance A. Liotta, Gordon Whiteley
-
Patent number: 8765143Abstract: An immunogenic fusion protein includes at least, on the C-terminal side, a first peptide composed of the S protein deleted of the transmembrane domain thereof located at the N-terminal end thereof, of a hepatitis B virus (HBV) isolate, and on the N-terminal side, a second peptide composed of the transmembrane domain and of the ectodomain of at least one envelope protein of a hepatitis C virus (HCV) isolate. A hybrid nucleic acid molecule encoding the fusion protein, and a vector including the hybrid nucleic acid molecule, a subviral particle including the fusion protein, an immunogenic composition including at least the fusion protein, or at least the hybrid nucleic acid molecule, or at least the subviral particle, and a cell line for the production of the fusion protein, or of the hybrid nucleic acid molecule, or of the subviral particle are described.Type: GrantFiled: June 16, 2009Date of Patent: July 1, 2014Assignee: Universite Francois Rabelais de ToursInventors: Philippe Roingeard, Christophe Hourioux, Romuald Patient
-
Publication number: 20140161826Abstract: A first composition comprising a ligand part being able to specifically bind to a target, the target being on a diseased cell of an organism, and an epitope part having a non-self epitope, or encoding a non-self epitope, the non-self epitope not naturally being encoded by the organism, wherein the target is internalized after forming a complex with the composition and the non-self epitope is presented on the cell surface of said diseased cell of an organism after internalization.Type: ApplicationFiled: April 5, 2012Publication date: June 12, 2014Inventor: Antonello Pessi
-
Patent number: 8734793Abstract: Recombinant antibodies, including chimeric antibodies, specific for hepatitis C (HCV) antigenic proteins are provided. The recombinant antibodies specifically bind to diagnostically relevant regions of HCV proteins and are thus suitable for use, for example, as diagnostic reagents for the detection of HCV, and/or as standardization reagents or positive control reagents in assays for the detection of HCV. The recombinant antibodies can also be used in the treatment or prevention of a HCV infection.Type: GrantFiled: November 22, 2010Date of Patent: May 27, 2014Assignee: Abbott Laboratories Inc.Inventors: Bailin Tu, Joan D. Tyner, James W. Scheffel, Michael K. White, Jeffrey M. Werneke, Robert N. Ziemann, David J. Hawksworth, Mary S. Pinkus, Robin A. Gutierrez
-
Patent number: 8728489Abstract: Disclosed are uses of immunotherapeutic compositions in combination with Standard of Care (SOC), or interferon therapy combined with anti-viral therapy, for the improved treatment of chronic hepatitis C virus (HCV) infection and related conditions, including liver function. The compositions, kits and uses of the invention, as compared to the use of SOC therapy alone: improves the rate of early response to therapy as measured by early virologic markers (e.g., RVR and EVR), enlarges the pool of patients who will have sustained responses to therapy over the long term, offers shortened courses of therapy for certain patients, enables “rescue” of patients who are non-responders or intolerant to SOC therapy, improves liver function and/or reduces liver damage in patients, and enables the personalization of HCV therapy for a patient, which can result in dose sparing, improved patient compliance, reduced side effects, and improved long term therapeutic outcomes.Type: GrantFiled: September 18, 2009Date of Patent: May 20, 2014Assignee: GlobeImmune, Inc.Inventors: David Apelian, Richard C. Duke, Alex Franzusoff
-
Patent number: 8728793Abstract: The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.Type: GrantFiled: July 14, 2008Date of Patent: May 20, 2014Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Jeffrey Glenn, Nam-Joon Cho, Curtis W. Frank, Kwang Ho Cheong
-
Patent number: 8715695Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.Type: GrantFiled: September 11, 2009Date of Patent: May 6, 2014Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen UniversityInventors: Ningshao Xia, Jun Zhang, Shaowei Li, Shengxiang Ge, Ying Gu, Zhiqiang He
-
Patent number: 8703149Abstract: The invention relates to the discovery that the Claudin-1 protein functions as a co-receptor for entry of HCV into cells. Methods of inhibiting, preventing or mitigating HCV infections by inhibiting HCV interactions with Claudin-1 are provided. Methods of identifying agents or compounds that interfere with HCV interactions with Claudin-1 are also provided. Finally, useful kits, cell culture compositions, agents, and compounds related to the inhibition of HCV interactions with Claudin-1 are also disclosed.Type: GrantFiled: August 23, 2011Date of Patent: April 22, 2014Assignee: The Rockefeller UniversityInventors: Charles Rice, Matthew J. Evans, Thomas Von Hahn
-
Publication number: 20140105931Abstract: This disclosure relates to viral particles and nucleic acids encoding an HCV envelope glycoprotein 2 containing a mutation. Viral particles can be created and administered to a subject to illicit an immune response.Type: ApplicationFiled: May 18, 2012Publication date: April 17, 2014Applicant: EMORY UNIVERSITYInventor: Arash Grakoui
-
Publication number: 20140065100Abstract: The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.Type: ApplicationFiled: November 8, 2013Publication date: March 6, 2014Applicant: Eisai R&D Management Co., Ltd.Inventors: Daniel P. Rossignol, Sally T. Ishizaka, Lynn D. Hawkins, Scott Fields
-
Patent number: 8663653Abstract: The present inventors developed hepatitis C virus 2b/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 2b reference strain J8. Sequence analysis of recovered 2b/2a recombinants from 2 transfection experiments revealed that 2b/2a was genetically stable. Conclusion: The developed 2b/2a viruses provide a robust in vitro tool for research in HCV genotype 2b, including vaccine studies and functional analysis.Type: GrantFiled: July 24, 2009Date of Patent: March 4, 2014Assignee: Hvidovre HospitalInventors: Judith M. Gottwein, Maria Lisa Knudsen, Troels Kasper Høyer Scheel, Jens Bukh
-
Publication number: 20140056943Abstract: The present invention relates to an immuno-stimulant combination for prophylaxis and treatment of hepatitis C, characterised in that it comprises: a TLR3 agonist, a CD40 agonist and the NS3 protein of the hepatitis C virus. Moreover, the invention relates to the pharmaceutical compositions comprising said immuno-stimulant combination, to the use thereof, and to a kit composed of said pharmaceutical compositions. Finally, the present invention relates to a method for producing an immune response to the hepatitis C virus and to a vaccine against said virus.Type: ApplicationFiled: September 27, 2013Publication date: February 27, 2014Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Aintzane ZABALETA AZPIROZ, Francisco BORRAS CUESTA, Jesus PRIETO VALTUENA, Pablo SAROBE UGARRIZA, Juan Jose LASARTE SAGASTIBELZA
-
Publication number: 20140023683Abstract: This invention provides methods for identifying HCV genomes and more specifically, methods for identifying nucleotide sequence of viral structural proteins at the time of HCV viral transmission. The method of the invention utilizes single genome amplification and sequencing of circulating virus as well as phylogenetic analysis of the resulting nucleotide sequence for identifying transmitted HCV genomes. Also provided are HCV genomes and corresponding nucleotide sequence for transmitted and circulating HCV virus. The invention further provides methods of administering a vaccine comprising one or more identified transmitted HCV sequences.Type: ApplicationFiled: September 8, 2011Publication date: January 23, 2014Applicants: THE UAB RESEARCH FOUNDATION, DUKE UNIVERSITYInventors: George M. Shaw, Hui Li, Beatrice H. Hahn, Barton F. Haynes
-
Patent number: 8618275Abstract: The present inventors developed 5a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and all of or part of NS2 were replaced by the corresponding genes of the genotype 5a reference strain SA13. Compared to the J6/JFH control virus, after transfection of in vitro transcripts in Huh7.5 cells, production of infectious viruses was delayed. However, in subsequent viral passages efficient spread of infection and HCV RNA titers as high as for J6/JFH were obtained. Infectivity titers were at all time points analyzed comparable to J6/JFH control virus. Sequence analysis of recovered 5a/2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in p7, NS2 and/or NS3. Infectivity of the 5a/2a viruses was CD81 and SR-BI dependant, and the recombinant viruses could be neutralized by chronic phase sera from patients infected with genotype 5a.Type: GrantFiled: May 19, 2008Date of Patent: December 31, 2013Assignee: Hvidovre HospitalInventors: Tanja Bertelsen Jensen, Judith M. Gottwein, Troels Kasper Høyer Scheel, Jesper Eugen-Olsen, Jens Bukh
-
Publication number: 20130344106Abstract: The present invention provides a new means of restoring the immune system in aging and immunocompromised individuals using an antioxidant nutraceutical. The nutraceutical stimulates the aging immune system through the Nrf2 master gene regulatory pathway. The invention is based in part on the discovery that the Nrf2 has antioxidant and immune restorative activity. The nutraceutical improves function of both the innate and adaptive immune systems.Type: ApplicationFiled: May 31, 2013Publication date: December 26, 2013Inventors: ANDRE E. NEL, HYON-JEEN KIM
-
Publication number: 20130323282Abstract: The present invention provides a composition comprising hepatitis C virus (HCV) Envelope 2 (E2) glycoprotein, wherein the HCV E2 is substantially monomer depleted HCV E2. Also provide are methods of inducing an HCV immune response.Type: ApplicationFiled: November 25, 2011Publication date: December 5, 2013Inventors: Heidi Drummer, Kathleen Mccaffrey, Pantelis Poumbourios
-
Patent number: 8569472Abstract: The present inventors developed hepatitis C virus 6a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 6a reference strain HK6a. Sequence analysis of recovered 6a/2a recombinants from 2 transfection experiments and subsequent reverse genetic studies revealed adaptive mutations in E1 and E2. Conclusion: The developed 6a/2a viruses provide a robust in vitro tool for research in HCV genotype 6, including vaccine studies and functional analysis.Type: GrantFiled: December 19, 2008Date of Patent: October 29, 2013Assignee: Hvidovre HospitalInventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Tanja Bertelsen Jensen, Jens Bukh
-
Patent number: 8563706Abstract: The present inventors developed hepatitis C virus 1a/2a and 1b/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and NS2 were replaced by the corresponding genes of the genotype Ia reference strain H77C or TN or the corresponding genes of the genotype Ib reference strain J4. Sequence analysis of recovered 1a/2a and 1b/2a recombinants from 2 serial passages and subsequent reverse genetic studies revealed adaptive mutations in e.g. p7, NS2 and/or NS3. In addition, the inventors demonstrate the possibility of using adaptive mutations identified for one HCV isolate in generating efficient cell culture systems for other isolates by transfer of mutations across isolates, subtypes or major genotypes. Furthermore neutralization studies showed that viruses of e.g. genotype 1 were efficiently neutralized by genotype Ia, 4a and 5a serum, an effect that could be utilized e.g. in vaccine development and immunological prophylaxis.Type: GrantFiled: December 19, 2008Date of Patent: October 22, 2013Assignee: Hvidovre HospitalInventors: Troels Kasper Hoyer Scheel, Judith M. Gottwein, Jannick Prento, Tanja Bertelsen Jensen, Jens Bukh
-
Publication number: 20130273101Abstract: The present invention relates to a pharmaceutical vaccine composition comprising: (a) a pathogen-derived antigen selected from the group consisting of Mycobacterium tuberculosis antigen, Bacillus anthracis antigen, HAV (hepatitis A virus) antigen, HBV (hepatitis B virus) antigen, HCV (hepatitis C virus) antigen, HIV (human immunodeficiency virus) antigen, influenza virus antigen, HSV (herpes simplex virus) antigen, Hib (Haemophilus influenzae type b) antigen, Neisseria meningitidis antigen, Corynebacterium diphtheriae antigen, Bordetella pertussis antigen, Clostridium tetani antigen and Varicella virus antigen; (b) a deacylated non-toxic LOS (lipooligosaccharide); and (c) a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 17, 2011Publication date: October 17, 2013Applicant: EYEGENE, INC.Inventors: Yang Je Cho, Na Gyong Lee, Jin Wook Jang, Kwang Sung Kim, Won Il Yoo
-
Patent number: 8541004Abstract: The invention relates to a peptidic compound containing a polyprotein NS3/NS4 of a hepatitis C virus and a polypeptide NS5b of hepatitis C virus. Said invention also relates to expression vectors such as adenovirus and poxyvirus in which nucleic sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b. The inventive compound can be used for a therapeutic application.Type: GrantFiled: September 23, 2011Date of Patent: September 24, 2013Assignee: Transgene S.A.Inventors: Anne Fournillier, Genevieve Inchauspe, Jean-Daniel Abraham, Maria Dimitrova-Tchomakov, Marie Parnot
-
Patent number: 8535686Abstract: The invention provides modified hepatitis C virus (HCV) E2 glycoproteins comprising the HCV-E2 receptor-binding domain (RBD) including the HVR1, HVR2 and igVR variable regions wherein in at least one of said variable regions at least a part of the variable region is replaced with a flexible linker sequence. The invention also provides vaccine compositions comprising the modified glycoproteins as well as methods of use thereof.Type: GrantFiled: August 24, 2007Date of Patent: September 17, 2013Assignee: The MacFarlane Burnet Institute for Medical Research and Public Health LimitedInventors: Kathleen McCaffrey, Heidi Drummer, Pantelis Poumbourios
-
Patent number: 8524868Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.Type: GrantFiled: November 9, 2009Date of Patent: September 3, 2013Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen UniversityInventors: Ningshao Xia, Jun Zhang, Shaowei Li, Shengxiang Ge, Ying Gu, Zhiqiang He
-
Publication number: 20130224246Abstract: A composition comprising a hepatitis C virus (HCV) Envelope 2 (E2) polypeptide including a receptor binding variant, wherein the polypeptide is modified to comprise: (i) a cysteine mutated or disrupted at 2, 3, or 4 cysteines selected from C452, C486, C569, and C597; and wherein the polypeptide forms substantially fewer multimers by intermolecular disulfide bonding relative to the HCV E2 polypeptide without cysteine modification, and substantially retains CD81 binding; and various uses thereof.Type: ApplicationFiled: August 4, 2011Publication date: August 29, 2013Inventors: Heidi Drummer, Kathleen McCaffrey, Pantelis Poumbourios
-
Patent number: 8506969Abstract: Genotype 7a has been identified recently, thus not much is known about the biology of this new, major HCV genotype. The present inventors developed hepatitis C virus 7a/2a intergenotypic recombinants in which the JFH1 structural genes (Core, E1 and E2), p7 and the complete NS2 were replaced by the corresponding genes of the genotype 7a strain QC69 and characterized them in Huh7.5 cells. Sequence analysis of 7a/JFH1 recombinants recovered after viral passage in Huh7.5 cells following 4 independent transfection experiments revealed adaptive mutations in Core, E2, NS2, NS5A and NS5B. In reverse genetic studies the importance of these mutations for improved growth kinetics was shown. Adapted 7a/JFH1 viruses showed growth kinetics, infectivity and RNA titers comparable to a previously developed 3a/JFH1 reference virus. Conclusion: The developed 7a/JFH1 viruses provide a robust in vitro tool for research in HCV genotype 7, including vaccine studies and functional analyses.Type: GrantFiled: July 31, 2009Date of Patent: August 13, 2013Assignee: Hvidovre HospitalInventors: Judith M. Gottwein, Troels Kasper Hoyer Scheel, Tanja Bertelsen Jensen, Jens Bukh
-
Publication number: 20130202554Abstract: Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen. In some embodiments, an isolated nucleic acid encoding hepatitis B core antigen (HBcAg) protein and a heterologous protein antigen is disclosed. Also disclosed herein are methods of administering the composition or isolated nucleic acid to generate an immune response, where HBcAg acts as adjuvant to improve the immune response to the heterologous protein. In certain embodiments, the HBcAg is as a stork or heron hepatitis antigen.Type: ApplicationFiled: April 3, 2013Publication date: August 8, 2013Applicant: CHRONTECH PHARMA ABInventor: CHRONTECH PHARMA AB